<DOC>
	<DOCNO>NCT00597116</DOCNO>
	<brief_summary>A clinical study assess new investigational drug effective treating malignant mesothelioma , compare chemotherapy treatment ( Navelbine® ) . In study patient assign chance receive either new drug chemotherapy treatment ( Navelbine® ) . Treatment continue long cancer worsen patient wish continue study . The study recruit approximately 66 patient .</brief_summary>
	<brief_title>An Efficacy Safety Study With Vandetanib Treat Inoperable Relapsed Malignant Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Diagnosed mesothelioma Previously treat one course chemotherapy mesothelioma No previous treatment vinorelbine No serious heart problem within last 3 month Serious abnormal laboratory value Severe uncontrolled disease condition judge Investigator Pregnant breastfeed woman Other cancer within last 5 year Major surgery radiation therapy within 4 week prior start study therapy Receipt investigational agent within 30 day prior commence study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Mesothelioma</keyword>
	<keyword>inoperable</keyword>
	<keyword>relapse</keyword>
</DOC>